Study guide

9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs

Key Takeaways Explain This Topic AI

Anatomic pathology and cytology reports are the highest-yield casefinding source, but relying on them alone misses clinically diagnosed, hematologic and outside-diagnosed cases.

The Health Information Management (HIM) disease index must be screened across ICD-10-CM codes C00–C96, D00–D09, D37–D48, D49, and benign CNS categories D32, D33, and D35.2–D35.4.

Diagnostic radiology casefinding targets interventional biopsy logs and BI-RADS category 4 (suspicious) and category 5 (highly suggestive of malignancy) mammography reports.

Non-surgical malignancies, including leukemias, lymphomas, and advanced outpatient cancers, are ascertained through medical oncology infusion logs and radiation oncology planning systems.

Electronic pathology (e-Path) screening utilizes automated keyword and SNOMED algorithms but requires mandatory ODS review to validate reportability and eliminate false positives.

Last updated: September 2026

9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs

To achieve complete case ascertainment, a cancer registry must build a comprehensive, multi-layered casefinding network. Relying on a single clinical feed—such as surgical pathology—guarantees significant under-reporting. Many hematologic malignancies, advanced unbiopsied neoplasms, outpatient radiotherapy cases, and benign central nervous system tumors never generate an inpatient surgical pathology specimen. Oncology Data Specialists (ODS-C) must understand the diagnostic characteristics and operational screening protocols across all facility data streams.

Anatomic Pathology & Cytology: The Surveillance Cornerstone

Anatomic pathology and cytology reports are the highest-yield casefinding source for solid tumors. Every tissue specimen processed through the hospital laboratory must pass through the registry casefinding filter.

1. Surgical Pathology Specimens

Biopsies: Excisional, incisional, punch, core needle, and endoscopic mucosal biopsies.

Resection Specimens: Complete organ resections (e.g., colectomies, mastectomies, prostatectomies, pneumonectomies) providing definitive pathological T and N categories and surgical margin status.

Frozen Section Consultations: Intraoperative pathological assessments that immediately flag provisional malignancies.

2. Bone Marrow Aspirates & Core Biopsies

Bone marrow documentation is essential for ascertaining hematologic and lymphoid neoplasms. These include acute leukemias (AML, ALL), chronic leukemias (CML, CLL), multiple myeloma, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) . Because these patients are frequently managed in outpatient hematology clinics without undergoing solid organ resection, reviewing bone marrow logs is vital to prevent severe ascertainment gaps.

3. Cytopathology & Fine-Needle Aspirations (FNA)

Cytology specimens evaluate exfoliated cells or aspirated fluid without intact tissue architecture:

Fine-Needle Aspirations (FNA): Thyroid nodules, palpable breast masses, salivary gland lesions, and suspicious lymph nodes.

Brushings & Washings: Bronchial brushings, bronchoalveolar lavage (BAL), esophageal brushings, and biliary duct brushings obtained during endoscopic retrograde cholangiopancreatography (ERCP).

Body Fluid Cytology: Pleural fluid, peritoneal/ascitic fluid, pericardial fluid, and cerebrospinal fluid (CSF). Positive cytology in pleural or peritoneal fluid frequently establishes distant metastatic disease (Stage IV / M1).

4. Autopsy Reports

Autopsy examinations capture unsuspected occult malignancies, confirm metastatic extent in ambiguous clinical deaths, and identify cancer cases that were completely undiagnosed during life. Cases identified solely at autopsy (where cancer was never suspected prior to death) are designated as Class of Case 38.

5. Electronic Pathology (e-Path) Screening Logic

Modern facilities implement automated e-Path interfaces that parse electronic laboratory feeds using natural language processing (NLP), SNOMED morphology codes, or diagnostic regex dictionaries. The algorithm automatically flags diagnostic keywords such as carcinoma , sarcoma , melanoma , lymphoma , blast , neoplasm , in situ , and high-grade intraepithelial .

Quality Control Alert: While e-Path drastically accelerates casefinding, it cannot replace human review. Automated engines generate frequent false positives (e.g., "negative for carcinoma" or "margins free of neoplasm") and false negatives (e.g., obscure histologic variants). The ODS must independently review each flagged record before clearing it to the abstracting queue.

Health Information Management (HIM) Disease Index Screening

The HIM Disease Index is an electronic master ledger generated from patient discharge and billing records, indexed by ICD-10-CM diagnostic codes . It serves as the primary safety net for catching cases that bypass the hospital pathology laboratory (such as patients biopsied at outside facilities, clinically diagnosed tumors, or patients admitted solely for systemic therapy). ┌─────────────────────────────────────────────────────────────────────────┐

  • │ ICD-10-CM NEOPLASM SCREENING RANGES │
  • └───────────────────────────────────┬─────────────────────────────────────┘
  • │
  • ┌─────────────────┬───────────────┴───────────────┬─────────────────┐
  • ▼ ▼ ▼ ▼
  • C00 – C96 D00 – D09 D37 – D48 D49
  • Malignant Carcinoma In Situ Uncertain Unspecified
  • Neoplasms Neoplasms Behavior Behavior
  • (All Primary (Oral, GI, Resp, (Must Screen (Provisional
  • & Secondary) Breast, Bladder) GIST, MDS, MPN) Diagnoses)
  • Core ICD-10-CM Neoplasm Code Categories to Screen

C00 – C96 (Malignant Neoplasms): Encompasses all primary invasive malignancies, secondary metastatic sites, and hematologic cancers. Every single C-code encounter must be screened.

D00 – D09 (In Situ Neoplasms): Encompasses carcinoma in situ of digestive organs, middle ear/respiratory system, breast, eye, and bladder. (Note: Cervical in situ D06 is non-reportable per national standards).

D37 – D48 (Neoplasms of Uncertain Behavior): Crucial screening category. Contains conditions that standard clinical coders categorize as uncertain, but which registry standards classify as reportable. This includes myelodysplastic syndromes (MDS) and chronic myeloproliferative neoplasms (MPN) , which ICD-O codes as malignant (/3), and malignant GIST and neuroendocrine tumors that clinical coders sometimes index as uncertain behavior. Borderline ovarian tumors (/1) are not reportable ; screen these codes, but accession only the conditions registry standards define as reportable.

D49 (Neoplasms of Unspecified Behavior): Identifies provisional clinical diagnoses where histology has not yet been obtained or documented. Screening D49 ensures clinically diagnosed tumors do not slip through registry surveillance.

Mandated Non-Malignant Brain & CNS Codes: Under Public Law 107-260, non-malignant brain and central nervous system tumors are reportable. Registrars must screen:

D32.0 – D32.9: Benign neoplasm of meninges (cerebral, spinal, unspecified).

D33.0 – D33.9: Benign neoplasm of brain and other parts of central nervous system (supratentorial, infratentorial, cranial nerves).

D35.2: Benign neoplasm of pituitary gland.

D35.3: Benign neoplasm of craniopharyngeal duct.

D35.4: Benign neoplasm of pineal gland.

Secondary & Encounter Codes:

Z85.0 – Z85.9: Personal history of malignant neoplasm (screens for patients receiving subsequent care or developing second primaries).

Z51.0: Encounter for antineoplastic radiation therapy.

Z51.11: Encounter for antineoplastic chemotherapy.

Z51.12: Encounter for antineoplastic immunotherapy.

Diagnostic Radiology & Nuclear Medicine Casefinding

Radiology and nuclear medicine reports identify patients with advanced, deep-seated, or clinically diagnosed neoplasms who never undergo surgical resection due to poor performance status, anatomical risk, or rapid decline.

Key Imaging Modalities Screened

Computed Tomography (CT) & Magnetic Resonance Imaging (MRI): Screened for definitive or suspicious masses of the brain, lung, pancreas, liver, and kidneys.

Positron Emission Tomography (PET/CT): Highly sensitive for hypermetabolic neoplastic lesions, regional lymph node involvement, and occult distant metastases.

Interventional Radiology (IR) Biopsy Logs: Tracks image-guided percutaneous biopsies (e.g., CT-guided lung core, ultrasound-guided liver core, fluoroscopic bone biopsy). These procedures are frequently performed in outpatient radiology suites and may fail to route to main surgical operating room ledgers.

Breast Imaging: BI-RADS Assessment Categories

Diagnostic mammography and breast ultrasound reports utilize the standardized Breast Imaging Reporting and Data System (BI-RADS) established by the American College of Radiology (ACR). Registrars must apply strict screening actions based on the assigned BI-RADS category:

BI-RADS Category Assessment Classification Malignancy Probability Casefinding & Registry Screening Action

BI-RADS 0 Incomplete Assessment Undetermined Non-reportable. Additional imaging or comparison views required before casefinding review.

BI-RADS 1 Negative Essentially 0% Non-reportable. Routine screening interval. Discard hit.

BI-RADS 2 Benign Finding Essentially 0% Non-reportable (e.g., simple cyst, stable fibroadenoma). Discard hit.

BI-RADS 3 Probably Benign < 2% Non-reportable. Short-interval follow-up (typically 6 months). Do not enter into suspense.

BI-RADS 4 Suspicious Abnormality >2% to <95% (4A, 4B, 4C) Suspense entry. Biopsy recommended. Track pending the histologic diagnosis.

BI-RADS 5 Highly Suggestive of Malignancy ≥ 95% Suspense entry. STORE: BI-RADS (and PI-RADS, LI-RADS) alone is not reportable for CoC. It becomes reportable when confirmed by biopsy or a physician's statement of cancer.

BI-RADS 6 Known Biopsy-Proven Malignancy 100% confirmed Active Case. Tissue diagnosis already confirmed. Locate surgical pathology report and begin abstraction.

Clinical Logs, Outpatient Clinics & Endoscopy Services

A resilient casefinding network incorporates non-pathology clinical and ambulatory service points across the healthcare system: ┌─────────────────────────────────────────┐

  • │ MULTIDISCIPLINARY CASEFINDING │
  • │ CLINICAL INTAKE MATRIX │
  • └────────────────────┬────────────────────┘
  • │
  • ┌───────────────────┬───────────────┴───────────────┬───────────────────┐
  • ▼ ▼ ▼ ▼
  • ┌──────────────┐ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
  • │ Radiation │ │ Medical │ │ Dermatology │ │ Endoscopy & │
  • │ Oncology │ │ Oncology │ │ & Outpatient │ │ Ambulatory │
  • │ Schedules │ │ Infusion Logs│ │ Biopsy Logs │ │ Surgical Logs│
  • └──────────────┘ └──────────────┘ └──────────────┘ └──────────────┘

Radiation Oncology Treatment Planning Systems: Software systems such as ARIA or MOSAIQ track simulation schedules, treatment planning prescriptions, and linear accelerator delivery logs. This is a critical source for capturing analytic cases that were diagnosed and resected at an external hospital but referred to the reporting facility for first-course adjuvant external beam radiotherapy.

Medical Oncology & Chemotherapy Infusion Ledgers: Pharmacy and infusion clinic scheduling logs capture patients receiving outpatient intravenous chemotherapy, targeted antibody therapy, or immunotherapy. This source is vital for ascertaining patients with metastatic disease managed non-operatively.

Dermatology & Ambulatory Biopsy Logs: Dermatologists and minor procedure suites frequently utilize private external commercial laboratories (e.g., Quest, Labcorp, Dermpath) rather than the hospital's in-house laboratory. Regularly auditing dermatology logs ensures the capture of invasive cutaneous melanomas, Merkel cell carcinomas, and genital skin carcinomas .

Endoscopy & Surgical Suite Registers: Procedure schedules from endoscopy suites (bronchoscopy, upper endoscopy, colonoscopy, cystoscopy, EUS) identify patients with visualized mucosal tumors where biopsies were sent to outside laboratories or where preliminary optical diagnosis warrants suspense tracking.

Comparison of Core Casefinding Sources

Source Category Screening Frequency Key Neoplasm Types Captured Operational Risk if Source is Omitted

Surgical Pathology & Cytology Daily / Continuous Solid organ carcinomas, sarcomas, in situ lesions, malignant effusions. Catastrophic failure; loss of 80%–90% of all standard hospital oncology cases.

Bone Marrow Logs Weekly / Monthly Acute/chronic leukemias, multiple myeloma, myelodysplastic syndromes. Severe ascertainment bias; complete omission of non-solid hematologic malignancies.

HIM Disease Index Monthly Unbiopsied clinical cancers, outpatient cases, benign CNS, readmissions. Failure to meet 95% completeness standard; loss of elderly or non-operative patients.

Radiation Oncology Logs Weekly / Monthly Cases diagnosed elsewhere receiving first-course radiotherapy (Class 20–22). Substantial loss of analytic treatment cases; distorted CoC quality metrics.

Dermatology Biopsy Logs Monthly / Quarterly Cutaneous melanoma, Merkel cell carcinoma, genital squamous carcinomas. Under-reporting of early-stage cutaneous malignancies and specialized histologies.

  • Practice Scenario & Exam Pitfalls
  • Clinical Practice Scenario

An 84-year-old female presents to the outpatient imaging center with a dense breast mass. Diagnostic mammography demonstrates an irregular, spicular mass with clustered pleomorphic microcalcifications measuring 3.5 cm, formally categorized as BI-RADS 5 (Highly Suggestive of Malignancy) . The patient has advanced dementia, and her healthcare surrogate declines core needle biopsy or surgical excision. The patient is placed on oral letrozole by her geriatrician and discharged to memory care. The cancer registry clerk asks whether this case is reportable without a pathology report.

ODS Regulatory Analysis: STORE 2025 states that BI-RADS, PI-RADS and LI-RADS categories alone are not reportable for CoC; they become reportable when confirmed by a biopsy or a physician's statement . The BI-RADS 5 report by itself does not make the case reportable. The ODS checks the geriatrician's note: if the physician documents a clinical diagnosis of breast cancer (for example, "presumed breast carcinoma; starting letrozole"), the case is reportable without microscopic confirmation (Diagnostic Confirmation code 7, radiography and other imaging techniques without microscopic confirmation), and the date of diagnosis is the date of that definitive physician statement. If no physician ever states a diagnosis of cancer, the case stays in suspense.

Core Exam Pitfalls to Avoid

Pitfall 1: Screening only C-codes in the HIM disease index. Registrars who screen only C00–C96 completely miss in situ lesions (D00–D09), benign brain and CNS tumors (D32, D33, D35.2–D35.4), and borderline conditions like GIST or MDS (D37–D48).

Pitfall 2: Discarding BI-RADS 4 mammography reports immediately. BI-RADS 4 indicates a suspicious lesion requiring biopsy. These cases must be entered into the Suspense File to track the forthcoming biopsy results, rather than being discarded.

Pitfall 3: Assuming all pathology is processed in the main hospital lab. Ambulatory surgery, endoscopy, and dermatology clinics often route specimens to commercial off-site pathology laboratories. Auditing facility procedural logs ensures these outsourced specimens are captured.

Loading diagram... Comprehensive Healthcare Facility Casefinding Intake and Triaging Matrix